Is GRI Bio, Inc. (GRI) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.9% / 30% | 222.0% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 1.9% / 33% | 222.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.8% / 33% | 95.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.9% / 33% | 222.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.8% / 33% | 95.0% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -238.2% | |
| Return on Assets (ROA) | -103.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$10M |
| Free Cash Flow | -$10M |
| Total Debt | $71,000 |
| Debt-to-Equity | 1.2 |
| Current Ratio | 3.3 |
| Total Assets | $9M |
Price & Trading
| Last Close | $2.28 |
| 50-Day MA | $3.11 |
| 200-Day MA | $32.12 |
| Avg Volume | 408K |
| Beta | -1.2 |
|
52-Week Range
$2.10
| |
About GRI Bio, Inc. (GRI)
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is GRI Bio, Inc. (GRI) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), GRI Bio, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is GRI Bio, Inc.'s debt ratio?
GRI Bio, Inc.'s debt ratio is 1.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.8%.
What are GRI Bio, Inc.'s key financial metrics?
GRI Bio, Inc. has a market capitalization of $3M. Return on equity stands at -238.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.